New CEO of Pfizer Ian Read discussed ongoing review of the society of business and research activities on a conference call with analysts Tuesday, which insisted all new plans to sell or spin off parts of the pharmaceutical giant.
Among those discussed are a unit that sells drugs have generic competition, called products established, and the one who sells drugs and those more recent, protected by a patent in emerging markets, including the Brazil, Russia, India, China, to the Mexico and the Turkey.
QUESTION: You narrowed your options regarding the different strategic options for your established products and new markets business? If you rotate or sell a portion of these companies, that you will do with the cash?
(Ian Reed, President and CEO of Pfizer) response: "we are still reviewing all of our alternatives outside the core business." ... I plan to during the second half suddenly go out with a detailed plan, but certainly we will take the decisions that we have taken and decisions us do not have and (at the time) give a clearer future. ... If turn us assets, the objective will return product to the shareholders. ?
No comments:
Post a Comment